Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Rhea-AI Summary
Pulmonx (Nasdaq: LUNG) will report its fourth quarter and full year 2025 financial results after market close on Wednesday, March 4, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET and a live archived webcast will be available on the company investor website.
Positive
- None.
Negative
- None.
News Market Reaction – LUNG
On the day this news was published, LUNG gained 1.76%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.0% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $62M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
With LUNG flat on the day, peers show mixed moves: names like APYX and XTNT are down while TELA is up, suggesting no clear, unified sector direction tied to this earnings-date announcement.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Inducement equity grants | Neutral | +8.0% | Large RSU and PSU grants under 2025 Inducement Plan for new executives. |
| Nov 12 | Q3 2025 earnings | Neutral | -6.2% | Q3 2025 results with revenue growth, high gross margin, and ongoing net loss. |
| Oct 27 | Management transition | Neutral | -4.9% | CEO change, new COO/CFO, executive departures, and preliminary Q3 revenue update. |
| Oct 15 | Earnings date notice | Neutral | -2.5% | Announcement of Q3 2025 earnings release date and conference call details. |
| Aug 26 | Investor conferences | Neutral | +5.1% | Planned participation in two September 2025 healthcare and growth conferences. |
Recent news—including earnings, management changes, and conference/earnings-date notices—has generally seen the stock move in the same direction as the perceived tone of the announcements, with no clear pattern of divergence.
Over the past six months, Pulmonx has reported Q3 2025 results with modest revenue growth but ongoing losses, announced leadership changes with updated executive compensation, and issued inducement equity grants tied to its 2025 Inducement Plan. It also communicated preliminary revenue and shifted earnings call timing, plus participated in investor conferences. This new notice of the Q4 and full-year 2025 earnings date continues the pattern of regular investor communications and scheduled updates following prior quarterly results and management transitions.
Regulatory & Risk Context
An effective Form S-3/A shelf dated 2025-11-24 allows Pulmonx to offer up to $200,000,000 of various securities over time, with proceeds earmarked for working capital, R&D, capital expenditures, and general corporate purposes. As of the latest data, there are 0 recorded usage events under this shelf.
Market Pulse Summary
This announcement sets the timeline for Pulmonx’s Q4 and full-year 2025 results and an accompanying conference call, continuing its pattern of regular investor updates. Shares trade below the 200-day MA and near the 52-week low, framing expectations heading into the release. Investors may focus on revenue growth, profitability trends, and cash usage, as well as how any future use of the $200,000,000 shelf registration could interact with the company’s capital needs.
AI-generated analysis. Not financial advice.
REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraX™ is a trademark of Pulmonx Corporation.
Contact
Brian Johnston
Laine Morgan
Gilmartin Group
investors@pulmonx.com
FAQ
When will Pulmonx (LUNG) release Q4 and full year 2025 results?
What time is the Pulmonx (LUNG) earnings conference call on March 4, 2026?
How can investors access the Pulmonx (LUNG) webcast for the March 4, 2026 results?
Will Pulmonx (LUNG) provide a replay of the March 4, 2026 earnings call?
What topics will Pulmonx (LUNG) management discuss during the March 4, 2026 call?
